In vitro susceptibility to ceftazidime/avibactam and comparators in clinical isolates of enterobacterales from five Latin American Countries

Autor: Tobias Manuel Appel, Elsa De La Cadena, Ana Cristina Gales, Marcela Alejandra Radice, Maria F. Mojica, Maria V. Villegas, Paulo F Castañeda-Mendez, Diego A Jaime-Villalón, Jose M. Munita, Christian Pallares
Přispěvatelé: Mojica, María Fernanda [0000-0002-1380-9824], de la Cadena, Elsa [0000-0003-0361-7893], Pallares, Christian José [0000-0002-6093-7845], Villegas, María Virginia [0000-0003-1898-9067]
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Carbapenem
Antibiotic susceptibility
Cephalosporin
Ceftazidime
Ciencias de la Salud
Tigecycline
Antimicrobial activity
Biochemistry
Ceftazidime/Avibactam
chemistry.chemical_compound
0302 clinical medicine
Enterobacterales
colombia
Pharmacology (medical)
030212 general & internal medicine
General Pharmacology
Toxicology and Pharmaceutics

Brief Report
chile
Enterobacter aerogenes
Otras Ciencias de la Salud
Klebsiella pneumoniae
Infectious Diseases
brazil
purl.org/becyt/ford/3 [https]
Ertapenem
geographic locations
medicine.drug
Microbiology (medical)
CIENCIAS MÉDICAS Y DE LA SALUD
medicine.drug_class
Avibactam
030106 microbiology
Argentina
Farmacorresistencia microbiana
Fosfomycin
Biology
Colombia
Microbiology
03 medical and health sciences
purl.org/becyt/ford/3.3 [https]
parasitic diseases
medicine
argentina
mexico
antimicrobial activity
lcsh:RM1-950
Ceftazidime/avibactam
lcsh:Therapeutics. Pharmacology
chemistry
Zdroj: Antibiotics, Vol 9, Iss 2, p 62 (2020)
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Antibiotics
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Popis: Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which hasshown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 andOctober 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% ofEnterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America Fil: Appel, Tobias Manuel. Universidad El Bosque; Colombia Fil: Mojica, Maria Fernanda. Universidad El Bosque; Colombia Fil: De La Cadena, Elsa. Universidad El Bosque; Colombia Fil: Pallares, Cristian. Universidad El Bosque; Colombia Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Castañeda Méndez, Paulo. Hospital Médica Sur; México Fil: Jaime-Villalón, Diego. Hospital San Angel; México Fil: Gales, Ana. Universidade de Sao Paulo; Brasil Fil: Munita, Jose. No especifíca; Fil: Villegas, Maria. Universidad El Bosque; Colombia
Databáze: OpenAIRE